three differ sub sector one consist messag trend
turn earli bullish
cautiou function busi complex messag tie
polit backdrop highlight
 share under-perform report higher expect
manag emphas cloud visibl multi factori driver
impact plan profit rest year
increas revenu guidanc reflect suspens medicaid elig
redetermin higher unemploy benefit special exchang
enrol period expect target maintain
manag emphas guidanc could chang clariti pace
individu return work manag expect pent demand
return earli continu anecdot convers
provid suggest elect procedur may back earli may/jun
watch back work cadenc chang medicaid contract
rollout state could end delay contract start focu north carolina
medicaid contract expect begin contribut new
member million revenu
iqvia share outperform manag outlin path recoveri
start return function
iqvia updat guidanc base recoveri path follow
china recoveri pace manag revis full-year revenu guidanc
billion account busi declin
backlog expect catch year end modest spill
 segment account total revenu headwind
clinic research site current access
manag expect site reopen site access
begin across therapeut area oncolog trial like come
back fastest due natur patient treatment importantli manag
advanc annual plan process expect provid
guidanc end suggest good visibl book busi
tidbit virtual trial pre-crisi level trial move
virtual enrol remot monitor covid-rel cancel
strong rfp momentum line oce resili technolog
analyt requir face-to-fac interact halt impact
bottom line immateri fix price contract base actual site visit
perform thu requir scope chang crisi current
work award pipelin potenti project
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
work heavili discount meaning book
 bullish tone call manag expect book volum
begin re-acceler hospit resum normal activ cadenc
increas opportun longer term strateg initi
near-term data analyt capabl get lift
covid crisi client turn data tool help project covid case
includ tool allow health system queri health data aw
recoveri stori hospit financi bandwidth capital-expenditure prioriti
emerg crisi manag express confid call
care act subsequ stimulu packag provid hospit fund
need resum even acceler spend cautiou state
non profit hospit account industri post-crisi
detail result
addit tidbit earn call
medicaid membership see benefit throughout year manag increas
revenu guidanc billion midpoint billion attribut
current econom environ special exchang enrol period suspens
medicaid elig redetermin higher unemploy expect drive
increas exchang medicaid membership largest medicaid book
member market share manag quantifi
membership growth expect behind increas revenu channel check
suggest medicaid enrol could grow low-double-digit high-teen
see commentari suggest compani alreadi seen earli evid
membership growth april manag expect major revenu
growth driven medicaid
premium payment delay new york delay million premium payment
quarter manag note subsequ paid collect
delay day manag highlight uncommon state
delay premium payment believ dynam could increas year given
covid context earn call unit note initi extend
payment collect period covid crisi increas percentag
premium extend collect timelin premium base typic
march premium april premium see
wellcar synergi delay due covid manag reiter expect
million run rate synergi deal note certain state like
georgia proactiv decid delay integr wellcar
plan result covid
updat estim base manag walk put take
reiter guidanc reduc ep estim in-
line guidanc maintain ep estim
revenu guidanc lower account divestitur covid impact
guidanc million impli y/i declin
midpoint lower prior rang million million
headwind consist million divestitur european asset spain
germani split announc impact covid
million million million impact split nearli half
covid revenu drag expect hit profession servic line
remaind split among resal softwar reimburs travel client
remain sidelin quarantin delay contract implement project start
book expect dip re-acceler book guidanc
million impli y/i declin declin
midpoint sequenti growth growth midpoint
compani note convers client still occur though new project
start project sign push due client focu address
covid alreadi initi underway compani mitig trend
perform remot servic work launch new project virtual
manag expect sale convers pick-up client get back work
margin take hit near-term cost improv track may
actual acceler come covid expect oper margin dip
near-term compani keep profession servic workforc near-
term expect implement volum return normal
oper margin expect full-year vs prior guidanc
vs prior margin improv initi continu
remain track initi implement continu posit
impact margin y/i lt margin improv platform modern
effort underway shift virtual remot work covid may result
long-term behavior chang client translat fewer on-site
visit travel expens go forward offer addit boost margin
result lower margin expect ep guidanc also reduc ep
guidanc ms/con ep guidanc
rang ms/con lower prior
servic
gener administr expens
amort intang
invest incom incom
incom continu oper
 revenu
tax rate hif
net incom continu oper
sell gener administr expens
depreci amort
incom oper restructur
incom oper
loss extinguish debt
incom incom tax equiti nci
incom equiti earn nci
equiti earn unconsolid affili
net loss incom attribut nci
net incom attribut iqvia
adjust ebit ebitda
depreci amort
ebit restructur impair
sale
million
revenu
sale client servic
cog revenu
sale client servic revenu
softwar develop revenu
gener administr revenu
multipl growth lever wcg rxadvanc execut success
calcul price target appli price-to-earnings multipl base case ep
multipl reect turn premium multipl premium reect
year averag discount adjust repeal hif estimate turn
largest medicaid player
market share
wellcar acquisit expand
market presenc medicar advantag
fastest grow market
stand-alone wellcar outperform
suggest potenti upsid deal accret
base estim break-even
mid-single-digit accret
addit upsid opportun
insourc pbm integr
medic pharmaci benet
repeal would headwind
assign low probabl outcom
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ep
premium multipl
premium multipl
in-lin year averag discount
adjust perman repeal
hif
ep
premium multipl
premium multipl
premium reect year averag discount
 adjust repeal hif estimate
ep
multipl
multipl discount in-
line stock trade
last price cycl
texa unit state constitution
view explan region hierarchi
research highest favor quintil
deal wcg drive acceler growth
margin perform high end
rxadvanc grow big market pharmaci
wcg out-performance drive upsid
loss core medicaid contract
exchang protabl less expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
data centric strategi gain share path acceler earn growth
dcf analysi use wacc perpetu growth rate
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings bull case ep
revenu growth come ahead guid
revenu growth come ahead guid
top-line compound-annual-growth-rate
ebitda growth
synergi ramp translat
ebitda compound-annual-growth-rate
price-to-earnings base case ep
 estim decreas backlog
convers april may
decreas last two
week march impli
y/i revenu declin site
monitor patient recruit
businesswhich account total
cro busi revenu
base estim
 model operatingmargin
bp contract y/i estim margin
expand
iqvia combin cro bellweth
integr clinic expertis
technolog asset leader futur
oce gain traction provid upsid
opportun drive organ
growth toward long term goal high
cut revenu synergi
provid earn boost next year
compani posit servic
pharma manufactur longer term drug
view descript risk reward theme
price-to-earnings bear case ep
growth miss mark
growth miss mark top-line compound-annual-growth-rate
ebitda growth
translat
ebitda compound-annual-growth-rate
quarterli book
strateg partnership larg pharma
quarterli result focu backlog growth
view explan region hierarchi
research highest favor quintil
oce contract fail materi
integr prove challeng
potenti loss delay larg contract
strateg partnerships/deploy lead
price pressur margin deterior
oce offer translat acceler top-line
growth margin expans
substanti runway growth opportun
smart clinic trial
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
lt growth depend new strateg initi partnership
dcf-deriv pt wacc medium-term growth rate termin
market leader global
ehr market account share
us market market alreadi
penetr greeneld opportun
hospit continu shift
spend area outsid core
popul key manag
deliv long-term top-line growth
strateg growth initi
consum employ medicaid
provid upsid option requir
increment invest outsid
cut initi expand
oper margin near-to-mid term
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings multipl appli bull
price-to-earnings multipl appli bull
case ep estim
case ep estim revenu
re-acceler high singl digit due
faster-than-expect uptak revenu
offer newer offer ebitda
margin expand beyond rang
multipl in-lin compar
softwar compani grow top-line
hsd ebitda margin
price-to-earnings multipl appli base
price-to-earnings multipl appli base
case ep estim
case ep estim revenu
grow low-mid single-digit
ebitda margin rang
impli multipl modestli
averag compar softwar compani
grow top-line lsd-msd
ebitda margin
view descript risk reward theme
price-to-earnings multipl appli bear case
price-to-earnings multipl appli bear case
ep estim
ep estim revenu growth
deceler low-single-digit
ebitda margin rang
multipl in-lin compar softwar
compani grow top-line lsd
ebitda margin
view explan region hierarchi
research highest favor quintil
faster expect ramp va contract
revenu acceler non-cor product
popul health itwork
expans hospit hcit budget
revenu deceler ebit declin
ration low-margin contract
lack traction non-cor product
implement delay va contract
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
